The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -12.44 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.29 — no flag raisedOK
- Earnings quality 68/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Akebia Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Product revenue, net$227.3M
- Auryxia$181.5M
- Vafseo$45.8M
- License, collaboration and other revenue$8.9M
- License Collaboration And Other Revenue, Royalties$1.8M
Leadership changes
From Akebia Therapeutics, Inc.'s own filings, the day they're filed.
- Ellen Snow · President · appointmenteff. 2023-07-17
- Merrimack College · Directors · appointment
- John Butler · Chief Executive Officer · departure
Latest filings
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
- DEF 14A · Annual proxy (pay & governance)2026-04-28
- 8-K · Company announcement2026-04-01
- 10-K · Annual report2026-02-26
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Akebia Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when Akebia Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.